Form 4: Edgewise Therapeutics Director Laura Brege Reports Stock Option Grant
SEC Form 4
Director Laura Brege reports the acquisition of stock options in Edgewise Therapeutics.
Summary
- Laura Brege, a director of Edgewise Therapeutics, reported a transaction on June 10, 2024.
- Brege acquired 20,594 stock options with an exercise price of $17.13.
- The options vest on the earlier of June 10, 2025, or the day before the 2025 annual meeting of stockholders and expire on June 10, 2034.
- Following the transaction, Brege directly owns 20,594 derivative securities.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Industry Context
This is a standard Form 4 filing, reflecting insider transactions in a publicly traded company. It is common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The grant of stock options aligns the director's interests with those of the shareholders, potentially incentivizing actions that increase shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of stock option grant |
| 06/10/2025 | Vesting date of stock options (or earlier if prior to the 2025 annual meeting) |
| 06/10/2034 | Expiration date of stock options |
| 06/12/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.